Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytoDyn Inc.CYDY · Entity 5856 | CMO | November 28, 2022 | December 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytoDyn Inc.
Report date November 28, 2022 · Filed December 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,184,037 |
Reported balance
After 2022-11-30 transaction · row 1
1 source rowRow 1 · 2022-11-30 · Grant · Acquired 16,927 · Balance 2,184,037 F1: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2032-11-28 | Direct | 2,315,439 |
Reported balance
After 2022-11-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-28 · Grant · Acquired 2,315,439 · Balance 2,315,439 F2: 241,190 shares vested on November 28, 2022; the balance will vest on a monthly basis as follows (i) 48,238 shares at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended), from November 2022 through February 2025, and (ii) 48,239 shares at the conclusion of each month of Continuous Service, from March 2025 through May 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 782,408 |
Reported balance
Holding disclosure · report date 2022-11-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 782,408 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary.
F2: 241,190 shares vested on November 28, 2022; the balance will vest on a monthly basis as follows (i) 48,238 shares at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended), from November 2022 through February 2025, and (ii) 48,239 shares at the conclusion of each month of Continuous Service, from March 2025 through May 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2022 Filed Dec 1, 2022 01:33 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 16,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-123365 · tm2231600-3_4seq1.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,184,037 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| November 28, 2022 Filed Dec 1, 2022 01:33 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 2,315,439 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001104659-22-123365 · tm2231600-3_4seq1.xml · derivative · entry 3 Kelly Scott A. · CIK 0001703394 · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,315,439 Underlying: Common Stock · 2,315,439 shares Expires 2032-11-28 F2 · derivative.exercise_date: 241,190 shares vested on November 28, 2022; the balance will vest on a monthly basis as follows (i) 48,238 shares at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended), from November 2022 through February 2025, and (ii) 48,239 shares at the conclusion of each month of Continuous Service, from March 2025 through May 2026. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 23:51 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 15,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-119979 · tm2230762-2_4seq1.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,167,110 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| October 31, 2022 Filed Nov 3, 2022 00:57 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 17,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-114101 · tm2228860-4_4seq1.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,151,876 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| October 15, 2022 Filed Oct 18, 2022 20:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 13,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-109687 · tm2228392-1_4seq1.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,133,954 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 23:19 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 18,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-105980 · tm2227293-1_4seq1.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,120,105 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 23:33 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 9,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-101258 · tm2226067-3_4seq1.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,101,312 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 23:57 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 11,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-097603 · tm2221304-7_4seq1.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,091,855 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 6,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-092174 · tm2221304-5_4seq1.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,080,761 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| July 31, 2022 Filed Aug 4, 2022 20:06 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 7,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-086117 · tm2222420-1_4seq1.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,073,811 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:02 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 13,112 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-080836 · tm2221304-1_4seq1.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,066,319 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:14 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 13,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-077432 · tm2220248-1_4seq1.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,053,207 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| June 15, 2022 Filed Jun 21, 2022 20:45 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 14,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-073001 · tm2218921-1_4seq1.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,039,471 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| May 31, 2022 Filed Jun 8, 2022 20:08 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 18,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069307 · tm2217755-4_4seq1.xml · nonDerivative · entry 5 Kelly Scott A. · CIK 0001703394 · Director · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,025,048 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| May 15, 2022 Filed Jun 8, 2022 20:08 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 16,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069307 · tm2217755-4_4seq1.xml · nonDerivative · entry 4 Kelly Scott A. · CIK 0001703394 · Director · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,007,019 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| April 30, 2022 Filed Jun 8, 2022 20:08 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 18,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069307 · tm2217755-4_4seq1.xml · nonDerivative · entry 3 Kelly Scott A. · CIK 0001703394 · Director · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,990,051 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| April 15, 2022 Filed Jun 8, 2022 20:08 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 21,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069307 · tm2217755-4_4seq1.xml · nonDerivative · entry 2 Kelly Scott A. · CIK 0001703394 · Director · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,972,022 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| March 31, 2022 Filed Jun 8, 2022 20:08 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 15,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069307 · tm2217755-4_4seq1.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,950,655 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 20:20 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 1,750,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0000899243-21-040761 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750,000 Underlying: Common Stock · 1,750,000 shares Expires 2031-10-18 F1 · derivative.exercise_date: The options will vest in 3 equal annual installments beginning on August 6, 2022, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:40 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon stock | 153,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032395 · doc4.xml · nonDerivative · entry 2 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,935,063 F2 · shares: Represents shares received in satisfaction of performance share award based on the achievement of specified performance goals for the fiscal year ended May 31, 2021, as determined by the issuer's compensation committee of the board of directors. F2 · price: Represents shares received in satisfaction of performance share award based on the achievement of specified performance goals for the fiscal year ended May 31, 2021, as determined by the issuer's compensation committee of the board of directors. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:40 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon stock | 40,661 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032395 · doc4.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,781,713 F1 · shares: Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors. F1 · price: Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors. Read SEC document |
| February 05, 2021 Filed Feb 5, 2021 14:08 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrant (right to buy) · Derivative | 166,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001807094-21-000001 · primary_doc.xml · derivative · entry 2 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 166,666 shares Expires 2021-02-10 Read SEC document |
| February 05, 2021 Filed Feb 5, 2021 14:08 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 166,000 | $0.75 | $124,500.00 |
DisclosureSEC source: 0001807094-21-000001 · primary_doc.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 782,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person disclaims beneficial ownership of the shares held by his spouse and this report should not be deemed an admission that the reporting person is the beneficial owner of his spouse's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:18 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 500,000 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001807094-20-000018 · primary_doc.xml · derivative · entry 2 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-06-15 F3 · date: The option grant was approved by a committee of the Issuer's Board of Directors on June 15, 2020, subject to stockholder approval of the Issuer's Amended & Restated 2012 Equity Incentive Plan (the "Plan") under which the option was granted. The Issuer's stockholders approved the Plan on September 30, 2020. F4 · derivative.exercise_date: The stock option vests annually in three equal installments beginning June 15, 2021. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:18 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 250,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001807094-20-000018 · primary_doc.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,741,052 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Amended & Restated 2012 Equity Incentive Plan. F2 · price: Not applicable. Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 18:57 UTC | CytoDyn Inc. CYDY · Entity 5856 | GiftCommon Stock | 74,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001807094-20-000016 · primary_doc.xml · nonDerivative · entry 2 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Indirect · By Custodian for daughter Disclosed balance after: 97,980 F1 · shares: This transaction involved a gift of securities by the spouse of the reporting person to her daughter, who shares reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his spouse and his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of either his spouse's shares or his daughter's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 18:57 UTC | CytoDyn Inc. CYDY · Entity 5856 | GiftCommon Stock | 74,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001807094-20-000016 · primary_doc.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 616,408 F1 · shares: This transaction involved a gift of securities by the spouse of the reporting person to her daughter, who shares reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his spouse and his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of either his spouse's shares or his daughter's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 05, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Option - right to buy · Derivative | 8,334 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · derivative · entry 22 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 8,334 shares Expires 2029-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option grant vests every four months beginning September 7, 2019. Read SEC document |
| May 04, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 8,334 | $0.52 | $4,333.68 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · nonDerivative · entry 10 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,566,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Stock Option-right to buy · Derivative | 8,334 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · derivative · entry 22 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 8,334 shares Expires 2029-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option grant vests every four months beginning September 7, 2019. Read SEC document |
| May 04, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 8,334 | $0.52 | $4,333.68 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · nonDerivative · entry 10 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,566,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Option - right to buy · Derivative | 93,750 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · derivative · entry 21 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,750 shares Expires 2029-10-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Option - right to buy · Derivative | 750,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · derivative · entry 20 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750,000 shares Expires 2029-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Option - right to buy · Derivative | 66,666 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · derivative · entry 19 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Stock · 66,666 shares Expires 2029-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option grant vests every four months beginning September 7, 2019. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Option - right to buy · Derivative | 250,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · derivative · entry 18 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2028-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Option - right to buy · Derivative | 100,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · derivative · entry 17 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Option - right to buy · Derivative | 97,009 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · derivative · entry 16 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,009 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Option - right to buy · Derivative | 75,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · derivative · entry 15 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2027-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Option - right to buy · Derivative | 7,123 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · derivative · entry 14 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,123 shares Expires 2027-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | SaleCommon Stock | 1,200,000 | $3.26 | $3,912,480.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · nonDerivative · entry 9 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,557,718 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.16 to $3.37. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 93,750 | $0.39 | $36,562.50 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · nonDerivative · entry 8 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,757,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 750,000 | $0.39 | $288,750.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · nonDerivative · entry 7 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,663,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 66,666 | $0.52 | $34,666.32 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · nonDerivative · entry 6 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,913,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | PurchaseCommon Stock | 250,000 | $0.57 | $141,250.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · nonDerivative · entry 5 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,847,302 Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 100,000 | $0.49 | $49,000.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · nonDerivative · entry 4 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,597,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 97,009 | $0.56 | $54,325.04 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · nonDerivative · entry 3 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,497,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 75,000 | $0.57 | $42,750.00 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · nonDerivative · entry 2 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:27 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 7,123 | $0.61 | $4,345.03 |
DisclosureSEC source: 0001807094-20-000006 · primary_doc.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,325,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Stock Option-right to buy · Derivative | 93,750 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · derivative · entry 21 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,750 shares Expires 2029-10-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 15, 2020 12:46 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNonqualified Stock Option-right to buy · Derivative | 750,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001807094-20-000007 · primary_doc.xml · derivative · entry 20 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750,000 shares Expires 2029-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.